TransCode Therapeutics Files For Offering Of Up To 10M Shares Of Common Stock
- SEC Filing
- SEC Filing
- SEC Filing
U.S. stocks traded slightly higher toward the end of trading, with the Dow Jones gaining by more than 50 points on Tuesday. The Dow traded up 0.17% to 40,483.92 while the NASDAQ rose 0.20% to 18,043.64. The S&P 500 also rose, gaining, 0.14% to 5,572.07. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 0.5% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline Coca-Cola Company (NYSE:KO) reported better-than-expected second-quarter results and raised its guidance. The company reported second-quarter FY24 sales growth of 3% year-on-year to $12.4
Transcode Therapeutics Inc (NASDAQ:RNAZ) shares are trading lower by 62% to $0.30 during Tuesday’s session after the company announced pricing of its public offering. The public offering of 10 million shares of its common stock will be at $0.30 per share, aiming to raise $3 million before deducting expenses. The offering is set to close on July 24, pending usual conditions. The funds will be used for product development, including clinical trials for TTX-MC138, their lead therapeutic candidate, and related studies as well as for general corporate purposes. Read Also: Veteran Wall Street Investor Downplays Recession Odds: ‘Current Bull Market Has More Support From Earnings’ Shoul
BOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, in collaboration with Michigan State University, published an article in the journal Oncotarget titled, Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties. The article was published on August 26, 2024. The study was led by Dr. Anna Moore, Professor, Director of the Precision Health Program, and Associate Dean of the School of Medicine at Michigan State University and scientific co-founder of TransCode. In this study, the authors show that stem-like breast cancer cells
BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate. TransCode has recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors. The clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138.
Two clinical trial sites activatedPatient enrollment expected this quarterTrial designed to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 BOSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced initiation of its Phase 1 multicenter, open-label, clinical study of its lead therapeutic candidate, TTX-MC138. Two clinical trial sites have been activated with patient enrollment expected to begin during the current quarter. TransCode may activate a total of up to five clinical trial sites, all of which are expected to be activate
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
10-Q - Transcode Therapeutics, Inc. (0001829635) (Filer)
SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13D - Transcode Therapeutics, Inc. (0001829635) (Subject)
SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company's Chief Medical Officer. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios. He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post–approv
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent business progress. "We continued to advance our therapeutic programs during the third quarter," said Michael Dudley, co-founder, president and CEO of TransCode. "We remain on track to achieve our planned milestones for 2H of 2022 which include submission of an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 clinical trial in up to 12 cancer patients with advanced solid tumors. We
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J. Slack, PhD, to its advisory board. "Dr. Slack is one of the most preeminent scientists in the field of small noncoding RNA," commented Zdravka Medarova, PhD, Co-Founder and CTO of TransCode. "Having pioneered pivotal studies proving that microRNAs drive oncogenesis and represent critical targets for the treatment of cancer, his guidance will prove indispensable as TransCode enters the clinical phase of development." Dr. Slack is the Shields Warren Mallinckrodt Profe